Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals Inc (NQ: CRNX )

49.38 +1.72 (+3.61%)
Streaming Delayed Price Updated: 11:25 AM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Crinetics Pharmaceuticals Inc

< Previous 1 2 3 Next >
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy & safety, with plans for FDA submission in 2024. 
Via Benzinga
Exposures Product Safety
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. 
Via Benzinga
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts
Via Benzinga
Crinetics Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win
Biotech stock Crinetics Pharmaceuticals rocketed early Tuesday after solid trial results for its oral growth hormone treatment. 
Via Investor's Business Daily
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Crinetics Pharmaceuticals Earnings Preview
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals
Via Benzinga
8 Analysts Have This to Say About Crinetics Pharmaceuticals
Via Benzinga
11 Analysts Have This to Say About Crinetics Pharmaceuticals
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
7 Speculative Stocks Set to Explode Higher
On the search for high-risk, high-reward opportunities? Consider taking a look at these seven speculative stocks. 
Via InvestorPlace
Top 4 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Why Crinetics Pharmaceuticals Stock Soared This Week
A positive late-stage trial readout fueled a major rally in the drugmaker's shares. 
Via The Motley Fool
Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?
Despite good results in phase 3 trials, there are barriers to its drug candidate's success. 
Via The Motley Fool
What's Going On With Crinetics Pharmaceuticals Stock?
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) shares are trading higher Tuesday. 
Via Benzinga
Nasdaq Rises Over 1%; Hostess Brands Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded up 0.29% to 34,676.52 while the NASDAQ rose 1.16% to 13,920.60. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Shares of Crinetics Pharmaceuticals Are Jumping Monday
The biotech company reported positive phase 3 trial results. 
Via The Motley Fool
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study... 
Via Benzinga
Gold Edges Higher; Virco Manufacturing Shares Surge After Q2 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 80 points on Monday. The Dow traded up 0.40% to 34,715.88 while the NASDAQ rose 0.58% to 13,841.50. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Crinetics Pharma's Investigational Candidate Shows Promise In Rare Type Of Hormonal Disorder
On Sunday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) said its Phase 3 PATHFNDR-1 study evaluating paltusotine met the primary and secondary  
Via Benzinga
Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 71%
The company is working on a treatment for a growth hormone disorder. 
Via Investor's Business Daily
US Stocks Open Higher; Dow Jumps 150 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.46% to 34,736.26 while the NASDAQ rose 0.94% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Nuwellis (NUWE) Stock Down Today?
Nuwellis (NUWE) stock is taking a beating on Monday despite a lack of news or increased trading activity for the medical device company. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.